Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV003066242 | SCV003353082 | pathogenic | Smith-Lemli-Opitz syndrome | 2022-05-13 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp371*) in the DHCR7 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 105 amino acid(s) of the DHCR7 protein. This variant is present in population databases (no rsID available, gnomAD 0.003%). A different variant (c.1112G>A) giving rise to the same protein effect has been determined to be pathogenic (Invitae). This suggests that this variant is also likely to be causative of disease. This variant disrupts a region of the DHCR7 protein in which other variant(s) (p.Phe475Ser) have been determined to be pathogenic (PMID: 15776424). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |